发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology 阿斯利康斥资2.4亿美元收购Moderna Therapeutics mRNA技术
Pharmadeals Review Pub Date : 2013-08-04 DOI: 10.3833/PDR.V2013I4.1918
Heather Cartwright
{"title":"AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1918","DOIUrl":"https://doi.org/10.3833/PDR.V2013I4.1918","url":null,"abstract":"AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Moderna will receive US$240 M upfront, which ranks as one of the largest initial payments ever disclosed for a discovery or preclinical-stage partnering deal. News of the collaboration came on the same day that AstraZeneca outlined a new strategy to revive growth that involves a significant overhaul of its R&D operations.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78902794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Celgene Partners with Bluebird Bio to Advance CAR T-Cell Cancer Therapies 新基与蓝鸟生物合作推进CAR - t细胞癌症治疗
Pharmadeals Review Pub Date : 2013-08-04 DOI: 10.3833/pdr.v2013i4.1919
Heather Cartwright
{"title":"Celgene Partners with Bluebird Bio to Advance CAR T-Cell Cancer Therapies","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i4.1919","DOIUrl":"https://doi.org/10.3833/pdr.v2013i4.1919","url":null,"abstract":"Celgene has partnered with Bluebird bio to discover, develop and commercialise novel disease-altering gene therapies in oncology that utilise a patient’s own genetically modified T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells selectively. Celgene has the option to license collaboration products on completion of each Phase I study; bluebird will be responsible for R&D up until this point. In a separate deal, Celgene has also formed a collaboration with the Center for Cell and Gene Therapy in the CAR T-cell field.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"30 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79512740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact Immunocore的imtac®平台获得大型制药公司的认可
Pharmadeals Review Pub Date : 2013-07-19 DOI: 10.3833/PDR.V2013I7.1967
Heather Cartwright
{"title":"Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1967","DOIUrl":"https://doi.org/10.3833/PDR.V2013I7.1967","url":null,"abstract":"Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87167633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine Avanir获得OptiNose治疗偏头痛的NDA-Ready药物装置组合的北美权利
Pharmadeals Review Pub Date : 2013-07-17 DOI: 10.3833/PDR.V2013I7.1966
Heather Cartwright
{"title":"Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1966","DOIUrl":"https://doi.org/10.3833/PDR.V2013I7.1966","url":null,"abstract":"Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine. The two companies will collaborate to complete the remaining activities needed to support regulatory submission of the drug-device combination, now known as AVP-825, with NDA filing expected by early 2014. If approved, AVP-825 will diversify Avanir’s CNS product portfolio beyond Nuedexta® (dextromethorphan plus quinidine sulphate), which is indicated for the treatment of pseudobulbar affect.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85896669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actavis Expands in Women’s Health with Uteron Pharma Purchase 阿特维斯扩大妇女健康与子宫制药收购
Pharmadeals Review Pub Date : 2013-07-02 DOI: 10.3833/PDR.V2013I2.1893
Heather Cartwright
{"title":"Actavis Expands in Women’s Health with Uteron Pharma Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1893","DOIUrl":"https://doi.org/10.3833/PDR.V2013I2.1893","url":null,"abstract":"Watson Pharmaceuticals, now officially known as Actavis, has acquired the Belgium-based women’s healthcare company Uteron Pharma in a deal worth up to US$305 M in order to expand its late-stage branded product pipeline. Levosert, an intrauterine device, is currently awaiting a regulatory decision in several EU countries and Diafert, an immunoassay kit for the assessment of oocyte quality during in vitro fertilisation, is expected to obtain a CE mark in the EU later in 2013. Actavis has been an active dealmaker in women’s health in recent years.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90345774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Medicines Company Strengthens its Perioperative Care Franchise via Deals with Incline Therapeutics and BMS 该公司通过与Incline Therapeutics和BMS的交易加强了其围手术期护理特许经营权
Pharmadeals Review Pub Date : 2013-07-01 DOI: 10.3833/PDR.V2013I1.1868
Heather Cartwright
{"title":"The Medicines Company Strengthens its Perioperative Care Franchise via Deals with Incline Therapeutics and BMS","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I1.1868","DOIUrl":"https://doi.org/10.3833/PDR.V2013I1.1868","url":null,"abstract":"The Medicines Company (TMC) has agreed to acquire Incline Therapeutics, which is pursuing the development of Ionsys® (fentanyl iontophoretic transdermal system), a needleless, patient-controlled analgesia device for the short-term management of acute postoperative pain. Cadence Pharmaceuticals obtained an exclusive option to acquire Incline in 2010 but this will be terminated on completion of the purchase of Incline by TMC. On the same day as the Incline deal, TMC also announced a 2-year global licence and collaboration agreement for Bristol-Myers Squibb’s Recothrom®, a US FDA approved topical recombinant thrombin to control non-arterial bleeding during surgery.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"84 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91512485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration 强生杨森生物技术公司投资微生物组研究与第二基因组合作
Pharmadeals Review Pub Date : 2013-06-26 DOI: 10.3833/PDR.V2013I6.1956
Heather Cartwright
{"title":"J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I6.1956","DOIUrl":"https://doi.org/10.3833/PDR.V2013I6.1956","url":null,"abstract":"In a first for the field, Johnson & Johnson’s Janssen Biotech has formed a strategic collaboration with start-up Second Genome to characterise therapeutic mechanisms in ulcerative colitis (UC) that are mediated by the microbiome, the bacterial ecosystem living in and on the human body. Janssen will provide R&D support to Second Genome, funded through the Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development. The big pharma company’s portfolio includes Remicade® (infliximab), which is used in the treatment of moderately to severely active UC.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89352974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration 辉瑞期待与巨细胞治疗公司合作开发下一代抗体-药物偶联物
Pharmadeals Review Pub Date : 2013-06-24 DOI: 10.3833/PDR.V2013I6.1954
Heather Cartwright
{"title":"Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I6.1954","DOIUrl":"https://doi.org/10.3833/PDR.V2013I6.1954","url":null,"abstract":"Highlighting its continued interest in the development of antibody-drug conjugates (ADCs), Pfizer has partnered with start-up CytomX Therapeutics to use the company’s Probody™ platform to develop multiple Probody-drug conjugates in oncology. CytomX’s Probodies are masked antibodies that remain inert in healthy tissue but which are activated by proteases in the tumour microenvironment. News of the deal comes only weeks after Pfizer discontinued a Phase III study of its ADC inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin’s lymphoma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75841548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase 阿斯利康收购Omthera制药，加强晚期心血管疾病产品线
Pharmadeals Review Pub Date : 2013-06-19 DOI: 10.3833/PDR.V2013I6.1952
Heather Cartwright
{"title":"AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I6.1952","DOIUrl":"https://doi.org/10.3833/PDR.V2013I6.1952","url":null,"abstract":"In its second cardiovascular disease-focused purchase of 2013, AstraZeneca has agreed to acquire Omthera Pharmaceuticals for approximately US$323 M plus Contingent Value Rights that equate to approximately US$120 M in total. With the acquisition, AstraZeneca will gain Omthera’s sole product candidate Epanova™, an omega-3 free fatty acid composition that has successfully completed two Phase III trials in patients with hypertriglyceridaemia and which will face competition in the prescription omega-3 market from GlaxoSmithKline’s Lovaza® (omega-3-acid ethyl esters) and Amarin’s Vascepa® (icosapent ethyl).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"13 44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77702736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seattle Genetics and Bayer Partner for a Second Time to Develop Antibody-Drug Conjugates 西雅图基因公司和拜耳公司第二次合作开发抗体-药物偶联物
Pharmadeals Review Pub Date : 2013-06-07 DOI: 10.3833/PDR.V2013I7.1962
Heather Cartwright
{"title":"Seattle Genetics and Bayer Partner for a Second Time to Develop Antibody-Drug Conjugates","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1962","DOIUrl":"https://doi.org/10.3833/PDR.V2013I7.1962","url":null,"abstract":"Bayer has formed a second antibody-drug conjugate (ADC) collaboration with Seattle Genetics under which it will obtain worldwide rights to utilise the company’s auristatin-based ADC technology with antibodies to several undisclosed cancer targets. Under the terms of the agreement, which is potentially worth US$520 M, Bayer is responsible for the research, development, manufacturing and commercialisation of all collaboration products. The two companies previously partnered in 2004 to develop an ADC against a single solid tumour target. This collaboration spawned BAY 79-4620, development of which was terminated in 2011.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"131 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91086674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信